{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-034218","form_type":"8-K","ticker":"ADTX","cik":"0001726711","company_name":"Aditxt, Inc.","filed_at":"2025-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.486283+00:00","generated_at":"2026-05-23T09:25:56.689536+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aditxt subsidiary Pearsanta receives IRB approval to begin clinical studies for endometriosis blood test","bullets":["Pearsanta received IRB approval to start clinical studies for a blood-based diagnostic test for endometriosis using mitochondrial DNA analysis.","Test uses Mitomic technology to detect disruptions in mitochondrial DNA from a blood sample; aims to replace invasive laparoscopic diagnosis.","Clinical validation targets ~100 samples from OB-GYN sites; commercial launch as an LDT targeted for end of June 2025.","Next test in pipeline is for prostate cancer; Richmond CLIA/CAP lab to process samples.","Collaborating with Evofem to recruit OB-GYN sites for the study; highlights synergies between subsidiaries."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-034218","json":"https://secwatch.observer/filing/0001213900-25-034218.json","markdown":"https://secwatch.observer/filing/0001213900-25-034218.md","text":"https://secwatch.observer/filing/0001213900-25-034218.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025034218/0001213900-25-034218-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025034218/ea0239164-8k_aditxt.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T09:25:56.689536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}